Youth Taking GLP-1 Medications For Obesity Have Less Suicidal Ideation

Youth prescribed a glucagon-like peptide 1 receptor agonist (GLP1R) medication for obesity had a 33% reduced risk for suicidal ideation or attempts over 12 months of follow-up. A total of 1.45% of those with a GLP1R prescription had suicidal ideation or attempts, compared to 2.26% of those without a GLP1R prescription.

Those with a GLP1R prescription had a higher rate of gastrointestinal (GI) symptoms over the 12-month follow-up period. A total of 6.9% of those on a GLP1R prescription had GI symptoms, compared to 5.4% of those without a GLP1R prescription. Despite . . .